The ACG has released new clinical guidelines for the management of ulcerative colitis and Crohn’s disease in adult ...

Starjemza (ustekinumab-hmny) was approved by the FDA this week as a biosimilar to Stelara. 2 A pair of clinical trials ...

Tremfya (guselkumab) is also the only drug in the class to achieve clinical remission and endoscopic response at one year with a fully subcutaneous treatment regimen, according to the drugmaker.

The expansion aims to help address the global shortfall of nu Johnson & Johnson (NYSE: JNJ) today announced new data from the Phase 3 ASTRO study evaluating TREMFYA® (guselkumab) subcutaneous (SC ...

and Tremfya (guselkumab), and Sun Pharma's Ilumya (tildrakizumab). In Crohn's, Skyrizi, Stelara, and Ilumya are already approved by the FDA, while Tremfya is under review, having been submitted to ...

The expansion aims to help address the global shortfall of nu Johnson & Johnson (NYSE: JNJ) today announced new data from the Phase 3 ASTRO study evaluating TREMFYA® (guselkumab) subcutaneous (SC) ...

The FDA designates 2 biosimilars as interchangeable, enhancing access to treatments for inflammatory diseases and multiple ...

Purpose: The characteristics of ideal intravenous (i.v.) and inhaled anesthetic agents; the rationale for inducing anesthesia with i.v. anesthetics (particularly propofol); therationale for ...

RA Remission Rates Vary in England and Wales Remission rates in rheumatoid arthritis vary on the basis of the region in England and Wales, with patients with longer symptom durations and time to ...